David Stern

Prior to Kindbody, Stern served as Chief Executive Officer of Boston IVF for five years, leading one of the nation’s largest and most respected fertility networks. Over the course of his distinguished three-decade career in the fertility and women’s health industries, he has held several key leadership positions. Notably, as CEO of Symbiomix Therapeutics, he spearheaded the company’s transition from development to the successful commercial launch of Solosec, culminating in its acquisition by Lupin Pharmaceuticals in 2017. Stern has also held senior executive roles at Merck Serono, where he served as Senior Vice President and Head of the Global Fertility Business Franchise, and at EMD Serono as Executive Vice President of Endocrinology within their biopharmaceutical division. His extensive experience further includes strategic leadership at Celmatix, Ohana, and OvaScience, where he was instrumental in building commercial teams, shaping corporate strategy, and expanding scientific partnerships across the women’s healthcare landscape. Stern holds an MBA with a concentration in International Marketing and Management from the F.W. Olin Graduate School of Business at Babson College, as well as a Bachelor of Science degree in Biology from Brandeis University.